Yusheng Han Buys 24,760 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 24,760 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $8.74 per share, with a total value of $216,402.40. Following the completion of the transaction, the director owned 17,697,436 shares of the company’s stock, valued at approximately $154,675,590.64. The trade was a 0.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han purchased 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han purchased 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 52-week low of $3.23 and a 52-week high of $41.72. The firm has a market capitalization of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32. The stock has a 50 day moving average price of $12.35 and a 200 day moving average price of $19.96. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Institutional Investors Weigh In On Burning Rock Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Crcm LP grew its stake in Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after purchasing an additional 269,851 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Burning Rock Biotech during the fourth quarter valued at about $220,000. Prospera Financial Services Inc boosted its holdings in shares of Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Institutional investors own 30.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.